Instil Bio, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 156.09 million compared to USD 223.18 million a year ago. Basic loss per share from continuing operations was USD 24 compared to USD 34.46 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.72 USD | +31.13% | +28.61% | +66.93% |
Jul. 12 | Instil Bio Shares Surge Following Rental Agreement with AstraZeneca | DJ |
Jul. 12 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.93% | 82.73M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- TIL Stock
- News Instil Bio, Inc.
- Instil Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023